CN116585479A - 西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 - Google Patents
西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 Download PDFInfo
- Publication number
- CN116585479A CN116585479A CN202310470698.2A CN202310470698A CN116585479A CN 116585479 A CN116585479 A CN 116585479A CN 202310470698 A CN202310470698 A CN 202310470698A CN 116585479 A CN116585479 A CN 116585479A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- small cell
- cell lung
- platinum
- tirelimumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 41
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 41
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 23
- 229940044683 chemotherapy drug Drugs 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 38
- 229910052697 platinum Inorganic materials 0.000 claims description 19
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 16
- 229960004316 cisplatin Drugs 0.000 claims description 16
- 229960005079 pemetrexed Drugs 0.000 claims description 13
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000009977 dual effect Effects 0.000 claims description 10
- 229960004562 carboplatin Drugs 0.000 claims description 9
- 190000008236 carboplatin Chemical compound 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 8
- 229960002798 cetrimide Drugs 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 7
- 229960003668 docetaxel Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- 229950007221 nedaplatin Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 5
- 229960002066 vinorelbine Drugs 0.000 claims description 5
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims description 4
- 229950008991 lobaplatin Drugs 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- -1 cyclothioplatin Chemical compound 0.000 claims description 3
- 190000005734 nedaplatin Chemical compound 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 238000002648 combination therapy Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- 229940125644 antibody drug Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000003902 lesion Effects 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960003349 pemetrexed disodium Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌的方法。在一项西达本胺联合替雷利珠单抗和化疗药物治疗晚期非小细胞肺癌的Ⅱ期临床研究中,客观缓解率(ORR)达到73.7%,疾病控制率(DCR)达到100%,中位无进展生存期(mPFS)达到13.8个月,此联合疗法效果优异。
Description
技术领域
本发明涉及生物医药领域,具体涉及西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌。
背景技术
肺癌是发病率及死亡率最高的恶性肿瘤。其中,非小细胞肺癌(NSCLC)是一大类,约占所有肺癌患者的80-85%,约70%的NSCLC患者在就诊时已经是不适合接受根治性手术的局部晚期或转移性肺癌,就算是早期和中期的NSCLC患者,在接受手术治疗后第三年就有一半以上患者发生复发或远处转移,而后因疾病进展死亡。
目前,免疫联合化疗已成为晚期NSCLC的标准治疗方案,但免疫治疗仍存在未被满足的临床需求,原发性耐药和获得性耐药是进一步改善局部晚期或转移性NSCLC患者的主要障碍。
西达本胺是深圳微芯生物科技股份有限公司自主研发合成的首个亚型选择性HDACi,是唯一被国家药品监督管理局批准可用于临床试验的HDACi类药物。西达本胺可改善肿瘤微环境,抑制肿瘤细胞周期,诱导肿瘤细胞凋亡,增敏免疫治疗,克服ICI耐药。
尽管存在众多治疗非小细胞肺癌的方案,但最终都易走向耐药而影响治疗。因此,对于发病率高,患者众多的非小细胞肺癌而言,仍需要探寻更好疗效的治疗方案。
发明内容
为了解决上述技术问题,本发明提供了一种西达本胺联合替雷利珠单抗和化疗药物在制备预防和/或治疗非小细胞肺癌药物中的用途。
第二方面,本发明也提供了一种治疗非小细胞肺癌的药物组合物,其包含西达本胺、替雷利珠单抗和化疗药物。
第三方面,本发明也提供了一种预防和/或治疗非小细胞肺癌的方法,包括向有需要的患者施用治疗有效量的第二方面所述的药物组合物。
现有的化疗药物种类繁多,例如铂类药物;卡培他滨、氟达拉滨、吉西他滨、培美曲塞等抗代谢物;阿霉素、柔红霉素、伊达比星、表柔比星等抗生素;托泊替康、伊立替康、依托泊苷、替尼泊苷等拓扑异构酶抑制剂;紫杉醇、多西他赛、长春碱、长春新碱、长春瑞滨等植物生物碱;泼尼松、甲基泼尼松龙和地塞米松等皮质类固醇。其中,铂类化疗药目前有三代药物,第一代为顺铂,第二代为卡铂和奈达铂,第三代为奥沙利铂和洛铂。
在一个实施方案中,所述化疗药物为含铂双药。
在一个优选的实施方案中,所述含铂双药选自铂类化疗药和第三代化疗药物的组合;所述铂类化疗药选自顺铂、卡铂、奈达铂、环硫铂、奥沙利铂、洛铂;所述第三代化疗药物选自紫杉醇、多西他赛、吉西他滨、长春瑞滨、依托泊苷或培美曲塞。例如所述含铂双药的组合为紫杉醇和顺铂(TP方案)、多西他赛和卡铂、培美曲塞和顺铂(PP方案)、培美曲塞和卡铂、多西他赛和顺铂(DP方案)、吉西他滨和顺铂(GP方案)、长春瑞滨和顺铂(NP方案)、多西他赛和奈达铂、依托泊苷和顺铂(EP方案)。
更优选地,所述含铂双药为培美曲塞和卡铂的组合或培美曲塞和顺铂的组合。
在一个实施方案中,所述非小细胞肺癌为晚期非小细胞肺癌。
在一个优选的实施方案中,所述非小细胞肺癌为未经治疗的晚期非小细胞肺癌。
在一个实施方案中,所述西达本胺的单位剂量为5-60mg,优选为20-30mg;所述替雷利珠单抗的单位剂量为100-200mg;所述化疗药物的单位剂量为10-500mg,优选10-200mg。
本发明申请人进行了西达本胺联合替雷利珠单抗和化疗药物治疗晚期非小细胞肺癌的Ⅱ期临床研究,研究结果发现此联合疗法具有突出疗效。在19例临床受试者中,客观缓解率(ORR)为73.7%(95%CI:63.6-83.8),疾病控制率(DCR)为100%。中位无进展生存期(mPFS)为13.8个月(95%CI:5.4-22.2),1年无进展生存期(PFS)率为76.6%。值得一提的是,本研究入组的一例高龄、不可手术的晚期肺腺癌受试者,在接受本方案治疗两周期后疗效评估为部分缓解(PR),且持续时间较长缓解持续时间(DoR)达到12个月,获得超14个月的无进展生存期(PFS),目前该受试者仍在维持治疗中。
与多项大型临床研究显示免疫联合化疗的中位无进展生存期(mPFS)为8.0-9.0个月相比,增加西达本胺联合治疗后无进展生存期增加5-6个月,效果显著,证明西达本胺与替雷利珠单抗和化疗药物有很好的协同作用,为晚期非小细胞肺癌患者提供了一种疗效优异的治疗方案。
本发明的技术术语:
在以下的描述中,阐述某些具体的细节以便提供对不同实施方案的透彻理解。然而,本领域技术人员应当理解,本发明可以在没有这些细节的情况下实施。在另外的情况下,没有详细地显示或描述公知的结构,以避免不必要地使实施方案的描述变得不清楚。除非上下文另有要求,否则在整个说明书和权利要求书中,词语“包括”及其变化形式,如“包含”和“含有”,应被解释为开放式的包含性含义,即“包括但不限于”。此外,本文提供的标题仅仅是为了方便起见,并非解释请求保护的发明的范围或含义。
贯穿本说明书提到的“一个实施方案”或“实施方案”意思是关于该实施方案描述的特定特征、结构或特性被包括在至少一个实施方案中。因此,在整个本说明书的不同地方出现的短语“在一个实施方案中”或“在实施方案中”并非必然全都指相同的实施方案。此外,特定的特征、结构或特性可以在一个或多个实施方案中以任何合适的方式组合。而且,如在本说明书和所附权利要求书中所用的,单数形式“一种”、“一个”和“该”包括复数的指示物,除非上下文另有明确规定。还应指出,除非上下文另有明确规定,否则术语“或”通常以包括“和/或”的含义使用。
术语“客观缓解率(ORR)”为获得完全缓解(CR)和部分缓解(PR)的患者占分析总人数的百分率。
术语“无进展生存期(PFS)”为从患者接受试验用药之日起到第一次出现疾病进展或死亡的时间长度。如果患者没有发生疾病进展或死亡事件,则PFS截止至最后一次肿瘤评估之日。
术语“疾病控制率(DCR)”为获得完全缓解(CR)和部分缓解(PR)以及疾病稳定(SD)的患者占分析总人数的百分率。
附图说明
图1代表可参与病灶缓解评估的19例患者肿瘤病灶相对于基线的缓解比率。
图2代表实际入组的20例患者的肿瘤缓解情况随治疗时间的变化情况。
图3代表患者无进展生存期(PFS)的情况。
具体实施方案
除非另外定义,本发明中所有的技术和科学术语与本发明所属技术领域的普通技术人员通常理解的含义一致。按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其他多种形式的修改、替换或变更。
下面通过实施例对本发明进行详细描述,但并不意味着对本发明任何不利限制。本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备,包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式,优选的实施方式包括但不限于本发明的实施例。对本领域的技术人员而言,在不脱离本发明精神和范围的情况下针对本发明具体实施方式进行各种变化和改进将是显而易见的,也应视为本发明的保护范围。
实施例1:西达本胺联合替雷利珠单抗和化疗治疗晚期非小细胞肺癌的Ⅱ期临床研究
一、患者入选标准
(1)年龄18-75岁;
(2)组织或细胞学证实的非小细胞肺癌,临床分期为IIIB-IV期,且未检测到EGFR/ALK突变或融合;
(3)既往针对晚期疾病未经治疗;若既往接受过新辅助/辅助化疗,则须末次化疗结束距入组至少6个月;
(4)ECOG评分0-1;
(5)至少有一个可测量病灶(按照RECIST v1.1评估标准);
(6)无脑转移或无症状的脑转移;
(7)性粒细胞绝对值≥1.5×109/L,血小板≥100×109/L,血红蛋白≥90g/L;
(8)预期生存时间≥3个月;
(9)筛选期提供肿瘤组织标本进行PD-L1表达等相关的检测;
(10)自愿参加本次临床试验,签署书面知情同意书。
二、实际入组受试者情况
共入组20例受试者,中位年龄63.5岁(范围:49-75岁),所有受试者均为男性,18位(90%)受试者有吸烟史,95%受试者为非小细胞肺癌Ⅳ期,8位(40%)为PD-L1阳性(PD-L1TPS≥1%)。
三、试验药物
(1)西达本胺片。规格:5mg。由深圳微芯生物科技股份有限公司提供。
(2)替雷利珠单抗。规格:10ml:100mg。由百济神州(上海)生物科技有限公司提供。
(3)化疗药物:注射用顺铂;规格:10mg。注射用培美曲塞二钠;规格:100mg,
500mg。均由齐鲁制药(海南)有限公司提供。
四、治疗方案
饭后30分钟口服西达本胺20mg/次或30mg/次,一周两次;静脉滴注替雷利珠单抗,200mg/次,三周一次,每疗程第一天用药;静脉滴注注射用培美曲塞二钠,500mg/m2,三周一次;静脉滴注注射用顺铂,85mg/m2,三周一次;。
每三周为一个治疗周期,化疗药物联合西达本胺和替雷利珠单抗治疗最多4个周期,此治疗周期内,西达本胺用药量20mg/次,用两周停药一周;化疗结束后继续西达本胺和替雷利珠单抗联合治疗,此时西达本胺用药量30mg/次;直至出现不可耐受的毒性、疾病进展、撤回知情同意书或死亡等。
五、有效性评价
主要终点指标为ORR(客观缓解率),次要终点指标为PFS(无进展生存期)、OS(总生存时间)、DCR(疾病控制率);
六、临床试验结果
(1)主要终点指标ORR
共有19例受试者可评估缓解情况,每例受试者肿瘤病灶的最佳缓解情况见附图1,每例受试者随治疗时间肿瘤的缓解情况见附图2,19例受试者缓解统计情况见下表1:
表1:肿瘤缓解情况
缓解 | 所有(N=19) | 腺癌(N=10) | 鳞癌(N=9) |
CR(完全缓解) | 1(5.3%) | 0 | 1(11.1%) |
PR(部分缓解) | 13(68.4%) | 6(60%) | 7(77.8%) |
SD(疾病稳定) | 5(26.3%) | 4(40%) | 1(11.1%) |
ORR(客观缓解率) | 14(73.7%) | 6(60%) | 8(88.9%) |
DCR(疾病控制率) | 19(100%) | 10(100%) | 9(100%) |
根据图1可知:1例受试者靶病灶相对基线缩小接近100%,评估为完全缓解(CR);13例患者靶病灶相对基线缩小30%以上,评估为部分缓解(PR),5例患者靶病灶相对基线缩小在30%以内,评估为疾病稳定(SD)。根据图2可知:大部分患者随之治疗时间的增加,肿瘤缓解情况逐渐好转。根据表1可知:客观缓解率(ORR)为73.7%(95% CI:63.6-83.8),疾病缓解率(DCR)为100%。
(2)次要终点指标PFS
受试者无进展生存期(PFS)情况见图3。
由图3可知:中位无进展生存期(mPFS)为13.8个月(95% CI:5.4-22.2),1年无进展生存期率为76.6%(95% CI:64.3%-88.9%)。
免疫联合化疗的中位无进展生存期(mPFS)为8.0-9.0个月,而本临床试验的中位无进展生存期为13.8个月,增长5-6个月。由此可知,在顺铂和培美曲塞含铂双药化疗的基础上,西达本胺联合替雷利珠单抗治疗非小细胞肺癌发挥协同作用。并且,从缓解率指标上可说明此四药联合疗法具有优异的抗肿瘤活性。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.西达本胺联合替雷利珠单抗和化疗药物在制备预防和/或治疗非小细胞肺癌药物中的用途。
2.如权利要求1所述的用途,其特征在于,所述化疗药物为含铂双药;
优选地,所述含铂双药选自铂类化疗药和第三代化疗药物的组合;所述铂类化疗药选自顺铂、卡铂、奈达铂、环硫铂、奥沙利铂、洛铂;所述第三代化疗药物选自紫杉醇、多西他赛、吉西他滨、长春瑞滨、依托泊苷或培美曲塞;更优选地,所述含铂双药为培美曲塞和卡铂的组合或培美曲塞和顺铂的组合。
3.如权利要求1所述的用途,其特征在于,所述非小细胞肺癌为晚期非小细胞肺癌;
优选地,所述非小细胞肺癌为未经治疗的晚期非小细胞肺癌。
4.如权利要求1所述的用途,其特征在于,所述西达本胺的单位剂量为5-60mg,优选为20-30mg;所述替雷利珠单抗的单位剂量为100-200mg;所述化疗药物的单位剂量为10-500mg,优选10-200mg。
5.一种预防和/或治疗非小细胞肺癌的药物组合物,其包含西达本胺、替雷利珠单抗和化疗药物。
6.如权利要求1所述的药物组合物,其特征在于,所述化疗药物为含铂双药;优选地,所述含铂双药选自铂类化疗药和第三代化疗药物的组合;所述铂类化疗药选自顺铂、卡铂、奈达铂、环硫铂、奥沙利铂、洛铂;所述第三代化疗药物选自紫杉醇、多西他赛、吉西他滨、长春瑞滨、依托泊苷或培美曲塞;更优选地,所述含铂双药为培美曲塞和卡铂的组合或培美曲塞和顺铂的组合。
7.如权利要求1所述的药物组合物,其特征在于,所述非小细胞肺癌为晚期非小细胞肺癌;
优选地,所述非小细胞肺癌为未经治疗的晚期非小细胞肺癌。
8.如权利要求5所述的药物组合物,其特征在于,所述西达本胺的单位剂量为5-60mg,优选为20-30mg;所述替雷利珠单抗的单位剂量为100-200mg;所述化疗药物的单位剂量为1-300mg,优选10-200mg。
9.一种预防和/或治疗非小细胞肺癌的方法,包括向有需要的患者施用治疗有效量的权利要求5-9所述的药物组合物。
10.如权利要求9所述的方法,其特征在于,所述非小细胞肺癌为晚期非小细胞肺癌;
优选地,所述非小细胞肺癌为未经治疗的晚期非小细胞肺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310470698.2A CN116585479A (zh) | 2023-04-25 | 2023-04-25 | 西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310470698.2A CN116585479A (zh) | 2023-04-25 | 2023-04-25 | 西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116585479A true CN116585479A (zh) | 2023-08-15 |
Family
ID=87598329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310470698.2A Pending CN116585479A (zh) | 2023-04-25 | 2023-04-25 | 西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116585479A (zh) |
-
2023
- 2023-04-25 CN CN202310470698.2A patent/CN116585479A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3076972B1 (en) | Cancer treatment with combination of plinabulin and taxane | |
Kaira et al. | A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer | |
Stathopoulos et al. | Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study | |
Mauer et al. | Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus | |
JP2011511071A (ja) | 肺癌を治療するためのピコプラチンおよびアムルビシン | |
EP1711188B1 (en) | Anti-cancer therapies | |
Wu et al. | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer | |
Duarte et al. | Combining repurposed drugs to treat colorectal cancer | |
US11000518B2 (en) | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer | |
CA3134156C (en) | Chiauranib for treatment of small cell lung cancer | |
Laudani et al. | Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma | |
Kelly et al. | A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer | |
CN116585479A (zh) | 西达本胺联合替雷利珠单抗和化疗药物治疗非小细胞肺癌 | |
CN112638385A (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
WO2022188491A1 (zh) | 一种肿瘤化疗药物组合物 | |
CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
CN115135326A (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
AU2012264408A1 (en) | Combined pharmaceutical compositions for the treatment of tumours | |
WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
CN117797151A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
WO2019155448A1 (en) | Methods and combination therapy to treat biliary tract cancer | |
Zhao et al. | Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer | |
CN113164503B (zh) | 3β-O-Glc-DM和20S-O-Glc-DM治疗肺癌或结直肠癌的用途 | |
US20230085602A1 (en) | Pdac treatment regimen | |
CN107456456A (zh) | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |